TrialHaematologica2018

Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data.

Artur C Fassoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.